{"id":496745,"date":"2020-07-17T13:34:01","date_gmt":"2020-07-17T13:34:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=496745"},"modified":"2020-07-17T13:34:01","modified_gmt":"2020-07-17T13:34:01","slug":"peripheral-tcell-lymphoma-ptcl-market-size-share-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/peripheral-tcell-lymphoma-ptcl-market-size-share-trends-epidemiology-forecast-till-2030_496745.html","title":{"rendered":"Peripheral T-Cell Lymphoma (PTCL) Market, Size, Share, Trends, Epidemiology Forecast till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Peripheral T-Cell Lymphoma (PTCL) Market, Size, Share, Trends, Epidemiology Forecast till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Peripheral T-Cell Lymphoma (PTCL) Market, Size, Share, Trends, Epidemiology Forecast till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Peripheral T-Cell Lymphoma (PTCL) Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Peripheral T-Cell Lymphoma (PTCL), historical and forecasted epidemiology as well as the Peripheral T-Cell Lymphoma (PTCL) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">Peripheral T-Cell Lymphoma (PTCL) is a diverse group of aggressive lymphomas that develop from mature T-cells and natural killer (NK) cells.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/peripheral-t-cell-lymphoma-ptcl-market\" target=\"_blank\">Peripheral T-Cell Lymphoma (PTCL) market<\/a> report provides current treatment practices, emerging drugs, Peripheral T-Cell Lymphoma (PTCL) market share of the individual therapies, current and forecasted Peripheral T-Cell Lymphoma (PTCL) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Peripheral T-Cell Lymphoma (PTCL) treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Highlights from the report:-<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>PTCL accounts for 7&ndash;15% of NHLs in the United Sates and EU-5 countries<\/li>\n<li>PTCL accounts for around 20&ndash;25% of NHLs in Japan&nbsp;<\/li>\n<li>EU5 countries occupied around 28.48% of the patient pool amongst 7MM in 2017<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">PTCL Treatment aims to cure and includes the use of combination chemotherapy regimens, localized radiotherapy, stem cell transplants and steroid therapy, etc.<\/p>\n<p style=\"text-align: justify;\">It is most often treated with a combination of chemotherapies which includes CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) and CHOEP or EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone).&nbsp;<\/p>\n<p style=\"text-align: justify;\">In some cases, stem cell or bone marrow transplant is recommended at the end of combination chemotherapy. The most commonly used steroids are prednisone, dexamethasone, and methylprednisone. They are used as a part of the combination chemotherapy regimen. For the Relapsed\/Refractory PTCL patients, Gemcitabine containing regimens are also being used as the conventional chemotherapy option.&nbsp;<\/p>\n<p style=\"text-align: justify;\">Later, to improve the poor outcome of PTCL patients, novel agents that target various pathways were manufactured. Hematopoietic stem cell transplant (HSCT) following a cytotoxic regimen constitutes yet another integral part of PTCL management comprising of both Autologous (auto-SCT) as well as Allogeneic Stem Cell Transplantation (allo-SCT). The success, however, depends upon the subtype of PTCL being treated and results are highly discordant.<\/p>\n<p style=\"text-align: justify;\">Apart from the available approved therapies, there are some off-label therapies and other emerging therapies that are available for PTCL treatment. Some of the off-label therapies which have been listed in the NCCN guidelines for Relapsed PTCL are MabThera (Rituxan), Bortezomib, Bendamustine, Lenalidomide, and Alemtuzumab.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The outcome was compared with a matched cohort of diffuse large B-cell lymphoma (DLBCL) patients, and prognostic factors were assessed using unilabiate and multivariate analyses.However, two approved drugs (Folotyn and Istodax) in Japan are rejected by the EMA due to a lack of evidence in the clinical benefit.<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Peripheral T-Cell Lymphoma (PTCL), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies<\/li>\n<li>Comprehensive insight has been provided into the Peripheral T-Cell Lymphoma (PTCL) epidemiology and treatment in the 7MM<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Peripheral T-Cell Lymphoma (PTCL) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape<\/li>\n<li>A detailed review of Peripheral T-Cell Lymphoma (PTCL) market; historical and forecasted is included in the report, covering drug outreach in the 7MM<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Peripheral T-Cell Lymphoma (PTCL) market<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/peripheral-t-cell-lymphoma-ptcl-market\" target=\"_blank\"><strong>Request for sample pages<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/uploads\/744a8b4f431dc704d1fe03591877b6f5.jpg\" alt=\"\" \/><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/peripheral-t-cell-lymphoma-ptcl-market\" target=\"_blank\"><strong>Table of contents<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary of Peripheral T-Cell Lymphoma (PTCL)<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intelligence Analysis for Peripheral T-Cell Lymphoma (PTCL)<\/p>\n<p style=\"text-align: justify;\">4. Peripheral T-Cell Lymphoma (PTCL): Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Peripheral T-Cell Lymphoma (PTCL): Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">6. Patient Journey<\/p>\n<p style=\"text-align: justify;\">7. Peripheral T-Cell Lymphoma (PTCL) Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">7.1. Epidemiology Key Findings<\/p>\n<p style=\"text-align: justify;\">7.2. Assumptions and Rationale: 7MM<\/p>\n<p style=\"text-align: justify;\">7.3. Epidemiology Scenario: 7MM<\/p>\n<p style=\"text-align: justify;\">7.3.1. Peripheral T-Cell Lymphoma (PTCL) Epidemiology Scenario in the 7MM (2017-2030)<\/p>\n<p style=\"text-align: justify;\">7.4. United States Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.4.1. Peripheral T-Cell Lymphoma (PTCL) Epidemiology Scenario in the United States (2017-2030)<\/p>\n<p style=\"text-align: justify;\">7.5. EU-5 Country-wise Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.2. France Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.4. Spain Epidemiology<\/p>\n<p style=\"text-align: justify;\">7.5.6. Japan Epidemiology<\/p>\n<p style=\"text-align: justify;\">8. Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n<p style=\"text-align: justify;\">9. Unmet Needs<\/p>\n<p style=\"text-align: justify;\">10. Key Endpoints of Peripheral T-Cell Lymphoma (PTCL) Treatment<\/p>\n<p style=\"text-align: justify;\">11. PTCL&nbsp;Marketed Products<\/p>\n<p style=\"text-align: justify;\">11.1. List of Marketed Products in the 7MM<\/p>\n<p style=\"text-align: justify;\">11.2. Drug Name: Company Name<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\">12. PTCL&nbsp;Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12.1. Key Cross<\/p>\n<p style=\"text-align: justify;\">12.2. Drug Name: Company Name<\/p>\n<p style=\"text-align: justify;\">List to be continued in report<\/p>\n<p style=\"text-align: justify;\">13. Peripheral T-Cell Lymphoma (PTCL): Seven Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">14. Attribute analysis<\/p>\n<p style=\"text-align: justify;\">15. 7MM: PTCL&nbsp;Market Outlook<\/p>\n<p style=\"text-align: justify;\">15.1. United States: Market Size<\/p>\n<p style=\"text-align: justify;\">15.2. EU-5 countries: Market Size and Outlook<\/p>\n<p style=\"text-align: justify;\">15.3. Germany Market Size<\/p>\n<p style=\"text-align: justify;\">15.4. France Market Size<\/p>\n<p style=\"text-align: justify;\">15.5. Italy Market Size<\/p>\n<p style=\"text-align: justify;\">15.6. Spain Market Size<\/p>\n<p style=\"text-align: justify;\">15.7. United Kingdom Market Size<\/p>\n<p style=\"text-align: justify;\">15.8. Japan Market Outlook<\/p>\n<p style=\"text-align: justify;\">15.8.1. Japan Market Size<\/p>\n<p style=\"text-align: justify;\">16. Access and Reimbursement Overview of Peripheral T-Cell Lymphoma (PTCL)<\/p>\n<p style=\"text-align: justify;\">17. KOL Views<\/p>\n<p style=\"text-align: justify;\">18. PTCL Market Drivers<\/p>\n<p style=\"text-align: justify;\">19. PTCL&nbsp;Market Barriers<\/p>\n<p style=\"text-align: justify;\">20. Appendix<\/p>\n<p style=\"text-align: justify;\">20.1. Bibliography<\/p>\n<p style=\"text-align: justify;\">20.2. PTCL Report Methodology<\/p>\n<p style=\"text-align: justify;\">21. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">22. Disclaimer<\/p>\n<p style=\"text-align: justify;\">23. About DelveInsight<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Priya Maurya<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=peripheral-tcell-lymphoma-ptcl-market-size-share-trends-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=peripheral-tcell-lymphoma-ptcl-market-size-share-trends-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight DelveInsight&#8217;s &#8220;Peripheral T-Cell Lymphoma (PTCL) Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Peripheral T-Cell Lymphoma (PTCL), historical and forecasted epidemiology as well as the Peripheral T-Cell Lymphoma (PTCL) market trends in the United &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/peripheral-tcell-lymphoma-ptcl-market-size-share-trends-epidemiology-forecast-till-2030_496745.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-496745","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=496745"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/496745\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=496745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=496745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=496745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}